$HRGN Cashflow Statement | Understand Stock

$HRGN

$2.35 +$0.05 (2.17%) Close

$HRGN Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
OPERATING ACTIVITIES
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Forgiveness of notes payable
Share-based compensation expense
Depreciation
Amortization of operating lease right-of-use assets
Change in fair value of warrant liability
Deferred financing costs

Changes in operating assets and liabilities:
Grant receivable
Accounts receivable
Inventory
Prepaid research and development
Prepaid expenses and other current assets
Deferred financing costs
Long-term prepaid contracts
Accounts payable
Operating lease liability
Accrual for contingency matter
Accrued and other current liabilities
Deferred revenue
Insurance premium financing payable
Net cash used in operating activities

Purchases of short-term investments
Redemption of short-term investments
Purchases of property, plant and equipment
FINANCING ACTIVITIES
Proceeds from notes payable
Acquisition of common stock for tax withholding obligations
Proceeds from convertible debt – related party
Related Party
Total proceeds from convertible debt – related party
Proceeds from issuance of common stock
Proceeds from exercise of warrants
Proceeds from exercise of stock options
Payments on convertible debt – related party
Related Party
Total payments on convertible debt – related party
Net cash provided by financing activities
Net (decrease) increase in cash and cash equivalents
Issuance of vested common stock
Settlement of contingency matter
Settlement of due to Harvard Bioscience included in accrued and other current liabilities
Cash and cash equivalents at the beginning of the year
Cash and cash equivalents at the end of the year

Effect of exchange rate changes on cash
SUPPLEMENTAL INFORMATION
Increase of right-of-use asset and liability due to lease extension
Interest paid in cash

Settlement of contingency matter
Settlement of due to Harvard Bioscience included in accrued and other current liabilities
Issuance of Series E convertible preferred stock
Supplemental disclosure of non-cash activities:
Preferred stock dividends
Increase of right-of-use asset and liability due to lease extension
Conversion of preferred stock into common stock
Right-of-use asset and lease liability (new lease)
Insurance premium financing

Comments